Change of Adviser

RNS Number : 0528M

Deltex Medical Group PLC

22 January 2009

 



Deltex Medical Group plc

Change of Adviser

22 January 2009 - Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the global leader in oesophageal Doppler monitoring ('ODM'), today announces with immediate effect the appointment of Arden Partners plc as its Nominated Adviser and Broker.

For further information, please contact:-

Deltex Medical Group plc                           01243 774 837

Nigel Keen, Chairman                                   [e-mail]

Andy Hill, Chief Executive                             [e-mail]

Ewan Phillips, Finance Director                     [e-mail] 

Nominated Adviser & Broker

Arden Partners                                          020 7398 1600

Chris Hardie                                                [e-mail]

Gavin Anderson & Company                     0207 554 1400

Deborah Walter                                           [e-mail]

Robert Speed                                              [e-mail]

Stuart Macaulay                                          [e-mail] 

Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already over 1,600 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. Over 1,000 patients a week are treated using the CardioQ-ODM. In addition, there are currently approximately 200 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

• Proved that the CardioQ-ODM works in a wide range of surgical procedures

• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

APPDFLFLKFBZBBB